InVivoSIM anti-human amyloid-beta (Solanezumab Biosimilar)
Catalog #SIM0047
Clone:
Solanezumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Solanezumab, making it ideal for research use. Solanezumab is a humanized IgG1Īŗ anti-human APP antibody, and it reacts preferentially with soluble monomers rather than fibrillar beta-amyloid or abeta. Solanezumab does not bind AĪ²ās aggregated forms. AĪ² is a peptide that is suggested to play a critical role in the pathogenesis of Alzheimerās disease (AD), and this peptide is generated through the aberrant protein processing of amyloid-Ī² protein precursor (APP or AĪ²PP). APP undergoes its initial cleavage by either Ī±- or Ī²-Secretase (or BACE1). Ī±-Secretase mediated cleavage of APP leads to the formation of sAPPĪ± and the Ī±-C-terminal fragment (Ī±-CTF or APP-C83). Ī²-Secretase cleaves sAPPĪ² and the Ī²-C-terminal fragment (Ī²-CTF or APP-C99). Ī³-Secretase further cleaves C99 and C83 to P3 and AĪ² respectively. AĪ²ās amino acid length can range from 37 to 43, depending on the location of Ī³-secretase cleavage and the two main AĪ² species are AĪ²42 and AĪ²40. AĪ²42 is present in amyloid plaques more frequently than AĪ²40, and AĪ² drives the basic neuropathological abnormalities in AD that are characterized by the presence of neurofibrillary tangles, i.e., intraneuronal protein clusters, composed of paired helical filaments of the hyperphosphorylated tau protein, a microtubule-associated protein, and extracellular AĪ² aggregates (senile plaques). Solanezumab recognizes a conformational epitope in the central region of human AĪ² (amino acid residues 16-26), thereby reacting with various N-terminally truncated species of AĪ² (e.g., Ab3-42) that are known to exist alongside full-length AĪ² (Ab1-42) in AD senile plaques. Preclinical studies involving the in vivo administration of Solanezumab have shown that this antibody promotes AĪ² clearance from the brain.Specifications
| Isotype | Human IgG1, Īŗ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Conjugation | This product is unconjugated. Conjugation is available via our Antibody Conjugation Services. |
| Immunogen | Human APP Abeta, soluble monomer |
| Reported Applications |
in vivo functional assays in vitro functional assays ELISA Western blot Immunohistochemistry (paraffin) |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<0.5EU/mg (<0.0005EU/Ī¼g) Determined by LAL gel clotting assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
>95% Determined by SDS-PAGE |
| Sterility | 0.2 Āµm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theilerās Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Recommended Products
-
Recommended Isotype Control(s)
RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer
